Physician profile
David B Scholl
NPI 1407994395
$777.11
in general payments reported to CMS, 2019-2025
14 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.38 · 2022: $80.25 · 2023: $180 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $128.62 | 2023-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $119.16 | 2021-2025 | Shingrix |
| Pfizer INC. | $101.81 | 2023 | |
| Novo Nordisk INC | $100.19 | 2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $66.09 | 2022-2025 | Repatha, Otezla |
| Lilly USA, LLC | $58.75 | 2025 | Jardiance, Mounjaro, Zepbound |
| Ibsa Pharma INC. | $42.84 | 2022-2025 | Licart, Flector, Tirosint |
| Abbott Laboratories | $41.05 | 2021-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $24.30 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $23.96 | 2025 | |
| Exact Sciences Corporation | $20.37 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $18.13 | 2025 | |
| Dexcom, INC. | $17.23 | 2025 | Dexcom G6 Transmitter |
| Insightec,INC | $14.61 | 2025 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Scholl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.